Riskpilot← Back to searchSign inGet full accessROS Therapeutics ApS
APSActiveCVR 39507501Veddelev Engvej 6Manufacture of pharmaceutical preparations · NACE 2120Est. 20181 employees
Revenue 2024
DKK -584K
-14% vs 2023
EBITDA margin
101.4%
+14% vs 2023
Equity ratio
-492.5%
Financial strength
Net profit 2024
DKK -1,3M
-14% vs 2023
| Revenue | DKK -584K | -14% |
| EBITDA | DKK -592K | +14% |
| Net profit | DKK -1,3M | -14% |
| Total assets | DKK 1,3M | -30% |
| Equity | DKK -6,6M | -25% |
| Employees | 1 | — |
Legal name
ROS Therapeutics ApS
CVR number
39507501
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
23. april 2018
Share capital
DKK 148.303
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af tre bestyrelsesmedlemmer eller af Selskabets administrerende direktør og bestyrelsesformanden i forening.
Company purpose
Selskabets formål er at drive farmaceutisk virksomhed samt anden virksomhed, der står i forbindelse hermed.
Address
Veddelev Engvej 6
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | -3.514 | -2.140 | -2.038 | -4.763 | -3.096 | -678 | -584 |
| Staff expenses | -504 | -203 | -151 | -605 | -616 | -13 | -8 |
| EBITDA | -4.018 | -2.343 | -2.188 | -5.368 | -3.712 | -690 | -592 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -4.018 | -2.343 | -2.188 | -5.368 | -3.712 | -690 | -592 |
| Net financials | -25 | -16 | -115 | -355 | -372 | -538 | -737 |
| Profit before tax | -4.043 | -2.359 | -2.303 | -5.723 | -4.085 | -1.228 | -1.329 |
| Tax | -851 | -476 | -403 | -1.341 | -734 | -76 | -14 |
| Net profit | -3.192 | -1.883 | -1.900 | -4.381 | -3.350 | -1.152 | -1.315 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 8.790 | 5.087 | 10.176 | 6.287 | 3.373 | 1.907 | 1.335 |
| Equity | 6.909 | 5.026 | 3.623 | -758 | -4.108 | -5.261 | -6.576 |
| Long-term debt | 0 | 0 | 5.915 | 6.132 | 6.432 | 6.941 | 7.628 |
| Short-term debt | 1.881 | 61 | 638 | 913 | 1.049 | 227 | 282 |
| Total debt | 1.881 | 61 | 6.553 | 7.045 | 7.481 | 7.168 | 7.911 |
EBITDA margin
-59175100.0%
This company
15.8%
Market median
-374526049% vs market
20182024
Equity ratio
-492.5%
This company
38.2%
Market median
-1389% vs market
20182024
Return on equity
-131491500.0%
This company
18.4%
Market median
-714627817% vs market
20182024
Net profit margin
-131491500.0%
This company
8.1%
Market median
-1623351952% vs market
20182024
Asset turnover
-0.44×
This company
1.12×
Market median
-139% vs market
20182024
Debt / equity
1.20×
This company
0.62×
Market median
-94% vs market
20182024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-04-23 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HD Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
ROS Therapeutics Holding ApS | Company | 50.0% | 50.0% | 2020 |
Sandlykke A/S | Company | 10.0% | 10.0% | 2020 |
HDJ & LEJ Invest ApS | Company | 5.0% | 5.0% | 2020 |
ROS Therapeutics ApS | Company | 10.0% | 10.0% | 2018 |
SPORCON LIFESCIENCE ADVISORS ApS | Company | 10.0% | 10.0% | 2019 |
INNOVATIONS A/S | Company | 5.0% | 5.0% | 2018 |
| Individual | 5.0% | 5.0% | 2018 | |
GreenOcean Capital ApS | Company | 5.0% | 5.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Gitte S. Holding ApS
ROS Therapeutics ApS Board members of ROS Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hanne Damgaard Jensen | Chief Executive Officer | 0 companies |
| Henrik Castenholm Fenger | Board of Directors | 0 companies |
| Mads Hartvig Clausen | Board of Directors | 0 companies |
| Morten Amstrup Sandlykke | Board of Directors | 0 companies |
| Christian Philip Hansen | Board of Directors | 0 companies |
| Anker Gunvald Lundemose | Board of Directors | 0 companies |
| Jon Bondebjerg | Board of Directors | 0 companies |
| Ricki Boye | Board of Directors | 0 companies |
| Ulrik Spork | Chairman | 0 companies |